SLP,
Independent Central Radiology Review
10
M o n th s
P r o g re s s io n - f r e e S u r v iv a l (% )
0
3
6
9
1 2
1 5
1 8
0
2 0
4 0
6 0
8 0
1 0 0
No. at Risk
Cabozantinib 187
152
92
68
20
6
2
Everolimus
188
99
46
29
10
2
0
Median PFS
No. of
Events
mo (95% CI)
Cabozantinib (N=187)
7.4 (5.6-9.1)
121
Everolimus (N=188)
3.8 (3.7-5.4)
126
Hazard ratio, 0.58 (95% CI 0.45-0.75, P<0.001
)
